从赤魟组织中分离到的福安肽的抗血管生成作用

目的研究从赤魟组织中分离到的福安肽(FAT)对鸡胚绒毛尿囊膜(CAM)血管生成、人低分化鼻咽癌细胞(CNE-2Z)诱导的CAM血管生成和小鼠肝癌组织血管生成的影响。方法用CAM法检测FAT对CAM血管生成和CNE-2Z细胞诱导的CAM血管生成的影响;用免疫组化法检查FAT对小鼠肝癌组织内微血管密度(MVD)的影响。结果FAT显著抑制CAM血管生成,当其用量为30,60,120μg/(胚.d)×3时,其抑制率分别为30.8%,50.1%,64.0%;CNE-2Z细胞明显诱导CAM血管生成,当CNE-2Z细胞的接种量为1.9×106细胞/胚时,其血管生成诱导率为30.1%;FAT明显抑制CNE-2Z细胞诱导的CAM血管生成,当其用量为30,60,120μg/(胚.d)×4时,其抑制率分别为35.8%,43.1%,51.3%。FAT明显降低小鼠肝癌组织的MVD,FAT平均微血管数为(8.2±1.3)与对照组的(21.3±2.8)相比,差异显著(P<0.05)。结论FAT有显著的抗血管生成作用,这可能是其抑制小鼠肿瘤生长的重要原因。     

咖啡酸锗对荷H22肝癌小鼠的抗肿瘤血管生成作用

目的 探讨咖啡酸锗体内抗H22肝癌血管生成的作用及其机制.方法 建立荷H22肝癌小鼠动物模型,随机分为5 组:生理盐水组(NS组,阴性对照组)、环磷酰胺组(阳性对照组)、咖啡酸锗低、中、高剂量组.尾静脉注射给药,采用体内抗肿瘤法观察咖啡酸锗对小鼠肿瘤组织的影响(抑瘤率),采用HE染色在光镜下观察各组小鼠的肿瘤血管生成情况,以及肿瘤细胞的生长情况,并应用免疫组化SP法检测各组小鼠肿瘤组织中血管内皮生长因子(VEGF)的表达.结果 与NS组比较,咖啡酸锗各剂量组瘤重均明显降低(P<0.01),咖啡酸锗低、中、高剂量组的抑瘤率分别为37.78%、48.89%、54.81%,咖啡酸锗各剂量组肿瘤血管数目比NS组明显减少(P<0.01),肿瘤细胞生长受抑,而坏死程度较严重.咖啡酸锗各剂量组肿瘤组织中VEGF的表达明显低于NS组(P<0.05).结论 咖啡酸锗对荷H22肝癌小鼠有明显的抗肿瘤血管生成作用,从而抑制肿瘤的生长,其机制可能与抑制肿瘤组织中VEGF的表达有关.     

福安泰-03对肿瘤血管生成的抑制作用

目的研究从赤魟组织中分离到的福安泰-03(Fuan-tai-03,FAT-03)对肿瘤血管生成的影响。方法鸡胚绒毛尿囊膜(CAM)法检测FAT-03对人低分化鼻咽癌细胞(CNE-2Z)诱导的CAM血管生成的影响;免疫组化法检查FAT-03对裸小鼠Lewis肺癌组织微血管密度(MVD)和血管生成因子表达的影响。结果FAT-03抑制CNE-2Z细胞诱导的CAM血管生成,当其用量为20、40、80、160μg/胚/d×5时,其抑制率分别为22.3%、34.3%、43.3%、46.2%。FAT-03降低小鼠Lewis肺癌组织的MVD,FAT-03组平均微血管数为9.1±1.5(对照组为18.2±3.2,P<0.05)。免疫组化检测结果显示,FAT-03明显下调小鼠Lewis肺癌组织血管内皮细胞生长因子(VEGF),碱性成纤维细胞因子(bFGF)和血小板衍生生长因子(PDGF)的表达。结论FAT-03有抗肿瘤血管生成作用,其作用与它的下调VEGF、bFGF和PDGF的表达密切相关。     

灵芝孢子油对H22荷瘤小鼠肿瘤生长及瘤细胞VEGF表达的影响

目的观察灵芝孢子油对荷H22瘤小鼠肿瘤生长及瘤细胞中血管内皮生长因子(vascular endothelial growth factor,VEGF)表达的影响,探讨该药抑制肿瘤的作用是否与抑制肿瘤血管生成有关。方法小鼠右腋皮下接种H22瘤细胞(浓度1×107/ml),0.2 ml/只,给药12天后,处死动物,剥离瘤块称重,计算肿瘤生长抑制率,用免疫组织化学法检测各组小鼠肿瘤组织中VEGF的表达程度。结果与模型组比较,灵芝孢子油对H22荷瘤小鼠肿瘤生长有明显抑制作用(P<0.05,P<0.01)。造模后各组小鼠VEGF均为阳性表达,灵芝孢子油各组可降低小鼠H22瘤组织中VEGF的阳性表达(P<0.05,P<0.01)。结论灵芝孢子油对H22移植性癌细胞生长有抑制作用,可降低瘤细胞中血管生成调控基因VEGF的表达。     

蝎毒多肽提取物抗肿瘤血管生成作用的实验研究

目的探讨东亚钳蝎蝎毒的多肽提取物PESV的抗血管生成活性和对肿瘤生长的抑制作用。方法①用不同浓度的PESV(4～20mg·L-1)作用于人脐静脉内皮细胞(HUVEC),采用BrdU参入的ELISA法观察HUVEC增殖活性和凋亡水平变化,流式细胞术检测凋亡细胞比例,免疫组化法检测Bal和Bax表达。②观察PESV对鸡胚尿囊膜(CAM)新生血管生成的影响。③皮下注射PESV(0.3mg·kg-1),观察对S180肉瘤和H22肝癌荷瘤小鼠肿瘤生长、肿瘤血管生成和血管生成因子(VEGF和bFGF)表达的影响。结果①体外实验显示,PESV在8～20mg·L-1范围明显抑制HUVEC的增殖活性(与对照组比较,P<0.01),而对乳腺癌细胞MDAMB231的增殖无影响;PESV作用后HUVEC凋亡细胞比例较对照组增加,P<0.05,Bax表达增加;Bcl2表达降低。②0.5mg/CAM和0.8mg/CAM的PESV能明显抑制CAM新生血管的形成。③体内实验显示PESV能明显抑制小鼠S180肉瘤和H22肝癌的肿瘤生长和血管生成水平,并降低肿瘤组织内血管生成相关因子VEGF和bFGF的表达。结论PESV具有良好的体内和体外抗肿瘤血管生成活性,并籍此抑制肿瘤的生长。     

赖氨酰谷氨酸二肽的抗肿瘤活性研究

目的研究二肽Lys-Glu(Vilon)的抗肿瘤活性。方法用液相法人工合成了抗肿瘤二肽Vilon,分子量为275.3。用细胞计数法和MTT法测定Vilon对人肠癌LOVO,人胃癌MKN45和人肝癌QGY77033种肿瘤细胞生长的抑制作用,以及对人体正常细胞生长的影响;并对其进行了体内实验。结果Vilon对体外培养的LOVO,MKN45和QGY7703细胞具有剂量依赖性抑制作用,但对人正常白细胞无明显抑制作用。体内抑瘤实验表明,Vilon对小鼠肝癌H22的生长有抑制作用,有效剂量为15mg.kg-1,当使用高剂量30mg.kg-1时,对小鼠移植性肿瘤肝癌H22的抑瘤率达0.60以上,且具有剂效关系。结论Vilon具有明显的体外、体内抗肿瘤活性。     

基因重组心肌肌钙蛋白Ⅰ融合蛋白的抗肿瘤效应

目的研究基因重组心肌肌钙蛋白I与人工短肽的融合蛋白(CIS)对肿瘤生长的作用。方法用MTT法观察CIS体外对人脐静脉内皮细胞(HUVEC)生长的作用。利用鸡胚绒毛尿囊膜模型观察CIS对新生血管生长的影响。用6种小鼠肿瘤异位可移植模型观察CIS在体内对肿瘤生长的作用。结果 CIS对HUVEC细胞增殖具有明显抑制作用,并呈剂量依赖关系;鸡胚绒毛尿囊膜实验显示,CIS浓度为5、10 mg·L~(-1)时,新生血管生成的数量明显减少;荷瘤鼠体内异位移植模型实验显示:CIS(10 mg·kg~(-1))处理组肿瘤生长缓慢,瘤体明显小于模型对照组,对S180肿瘤瘤重抑制率85.3%,对Lewis肺癌肿瘤瘤重抑制率87.0%,对H22肝癌肿瘤瘤重抑制率84.2%,对人小细胞肺癌H446肿瘤瘤重抑制率60.42%,对人可移植性肝癌SMMC7721肿瘤瘤重抑制率61.62%,对人胃低分化腺癌BGC823肿瘤瘤重抑制率为41.84%。结论 CIS在体外抑制HUVEC细胞的生长,在鸡胚绒毛尿囊膜实验中,CIS对新生血管生成有明显的抑制作用。在体内,CIS融合蛋白可有效抑制小鼠可移植肿瘤细胞的生长。CIS抗肿瘤效应很可能是通过抑制肿瘤组织中血管内皮细胞的增殖,进而减少肿瘤组织中新生血管生成的数量而达到的。     

5-FU经不同途径区域化疗影响大鼠肝癌血管生成的研究

目的:通过对大鼠移植性肝癌进行不同途径区域灌注化疗,研究不同给药途径下化疗对肿瘤血管生成的影响。方法:建立大鼠移植性原位肝癌模型,分别经大鼠外周静脉,肝动脉,门静脉,肝动脉结扎的门静脉注射5-FU,给药剂量为20mg/kg,连续给药4天,采用免疫组化法检测VEGF和CD34在不同途径区域化疗下肝癌组织中的表达及光镜下计算肿瘤内微血管密度。结果:外周静脉组全身化疗的肝癌VEGF表达显著高于其它3个区域性灌注化疗组,区域性灌注化疗的3个化疗组中,门静脉组的VEGF表达明显高于肝动脉组和结扎肝动脉的门静脉组(P<0.05);结扎肝动脉的门静脉组肝癌组织的CD34蛋白表达和MVD最低,明显低于其他四组(P<0.05)。结论:区域性灌注化疗可有效抑制肝癌血管生成;区域性灌注化疗抗肿瘤血管生成的机制可能是抑制肿瘤组织VEGF的表达,减少肿瘤组织内血管生成,并使MVD降低,从而抑制肿瘤生长。     

蚯蚓纤溶酶的抗肿瘤作用

目的　观察蚯蚓纤溶酶 (EFE)对体外人癌细胞株及体内人癌裸鼠移植性肿瘤生长的影响 ,对该药进行临床前抗肿瘤药效学评价。方法　采用MTT法观察蚯蚓纤溶酶对体外人癌细胞的生长抑制作用 ;用人胃癌BGC82 3和人乳腺癌B37裸鼠移植性肿瘤模型对蚯蚓纤溶酶进行体内抗肿瘤药效学观察。结果　蚯蚓纤溶酶在体外对人癌细胞的生长无抑制作用 ;灌胃给予蚯蚓纤溶酶 2 0 0～ 10 0 0mg·kg-1,可明显抑制人胃癌BGC82 3和人乳腺癌B37裸鼠移植性肿瘤的生长。结论　蚯蚓纤溶酶具有抗肿瘤作用。     

重组人内抑素的抗肿瘤活性

目的观察重组人内抑素抗肿瘤活性及对血管内皮细胞增殖的抑制作用。方法用人癌裸鼠移植性肿瘤及小鼠移植性肿瘤模型对重组人内抑素进行抗肿瘤药效学观察,用MTT法观察其对血管内皮细胞及肿瘤细胞增殖的抑制作用。结果重组人内抑素,可明显抑制人胃癌BGC803和人乳腺癌B37裸鼠移植性肿瘤的生长,对小鼠肝癌H22实体瘤亦呈一定的抑制作用。MTT试验结果显示重组人内抑素可抑制人胎脐静脉血管内皮细胞ECV304的增殖,对人结肠癌HCT-8等肿瘤细胞的增殖无影响。结论重组人内抑素具有较强的抗肿瘤作用,其作用机理可能与抑制血管内皮细胞增殖、抑制肿瘤新生血管形成有关。     

Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells

The present study was designed to select the effective dosage range of Z24 [3Z-3-[(1H-pyrrol-2-yl)-methylidene]-1-(1-piperidinylmethyl)-1,3-2H-indol-2-one], a novel synthetic indolin-2-ketone small-molecule compound, against tumorigenesis and angiogenesis in vitro and in vivo and to investigate the primary action mechanism of Z24 on the angiogenesis by comparing with SU5416 [3-[(2,4-dimethylpyrrol-5-yl)methyllidenyl]-indolin-2-one] in the selective effects on vascular endothelial growth factor (VEGF)/basic fibroblast growth factor (bFGF) signaling and Bcl-2-related cell vitality because Z24 is a potential inhibitor of the Bcl-2 that inhibits growth of multiple tumor types in vivo in our previous study. Per os Z24 inhibited dose-dependently the mouse S180 xenograft tumor growth and angiogenesis in mouse subcutaneous (s.c.) Matrigel plugs in vivo. The maximum growth inhibitory rate was 56.1% by 80 mg/kg/day on S180 mouse sarcoma cells; however, the maximum inhibitory potency on angiogenesis in C57BL/6 mouse subcutaneous Matrigel plug model was 50 mg/kg/day. Z24 inhibited angiogenesis in chicken chorioallantoic membrane (CAM) and invasion and inhibited tube formation of endothelial cells in a dose-dependent manner. Compared with SU5416, the IC50 (50% inhibition concentration) of Z24 on the proliferation of ECV-304 carcinoma cells induced by VEGF or bFGF was 24.4 and 17.99 microM, respectively, which is higher or lower, respectively, than that of SU5416 (14.2 microM for VEGF and 22.7 microM for bFGF). Furthermore, the IC50 of Z24 on the proliferation of Bcl-2 over-expressing HeLa cells and non-Bcl-2-expressing (wild-type) HeLa cells are 11.9 and 24.8 microM, respectively. SU5416 did not exert such a selective inhibiting effect on Bcl-2 over-expressing HeLa cells. These results suggest that Z24 per os has dose-dependent antitumor and antiangiogenesis pharmacological activity. The higher selectivity of Z24 on Bcl-2 protein and on bFGF other than VEGF signaling path may contribute to its efficiency against tumor and tumor-associated angiogenesis.     

血管内皮细胞生长因子、碱性成纤维细胞生长因子在正常成人皮肤中的表达及其意义

目的探讨两种促血管生成因子血管内皮细胞生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)在正常成人皮肤组织中的表达及其意义.方法采用免疫组化SP法检测20例正常成人皮肤组织VEGF、bFGF的表达及分布.结果正常成人皮肤组织中,VEGF、bFGF阳性细胞均主要位于基底层,呈弱阳性表达.结论正常成人皮肤组织中,基底层是表达VEGF、bFGF的主要细胞,在维持真皮微血管的正常生理功能中可能发挥重要作用.     

Beta-eudesmol suppresses tumour growth through inhibition of tumour neovascularisation and tumour cell proliferation

In the present study, we investigated the potential anti-angiogenic mechanism and anti-tumour activity of beta-eudesmol using in vitro and in vivo experimental models. Proliferation of human umbilical vein endothelial cells (HUVEC) stimulated with vascular endothelial growth factor (VEGF, 30 ng/ml) and basic fibroblast growth factor (bFGF, 30 ng/ml) was significantly inhibited by beta-eudesmol (50-100 microM). Beta-eudesmol (100 microM) also blocked the phosphorylation of cAMP response element binding protein (CREB) induced by VEGF (30 ng/ml) in HUVEC. Beta-eudesmol (10-100 microM) inhibited proliferation of HeLa, SGC-7901, and BEL-7402 tumour cells in a time- and dose-dependent manner. Moreover, beta-eudesmol treatment (2.5-5 mg/kg) significantly inhibited growth of H(22) and S(180) mouse tumour in vivo. These results indicated that beta-eudesmol inhibited angiogenesis by suppressing CREB activation in growth factor signalling pathway. This is the first study to demonstrate that beta-eudesmol is an inhibitor of tumour growth.     

Effect of gelatin on heparin regulation of cytokine release from hyaluronan-based hydrogels

The hypothesis that incorporation of small amounts (0.3% w/w) of modified heparin in thiol-modified hyaluronan or HA and gelatin hydrogels would regulate release of cytokine growth factors (GFs) from those gels has been investigated in vitro. In addition, the physiologic response to gel implantation has been evaluated in vivo. Tests were performed with 6 GFs: basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1), keratinocyte growth factor, platelet-derived growth factor-AA (PDGF), and transforming growth factor-beta 1. Release profiles for all 6 over several weeks were well fit by first order exponential kinetics (R(2) > 0.9 for all cases). The most remarkable result of the experiment was a dramatic variation in the total mass ultimately released, which varied from as much as 90.2% of the initial load for bFGF to as little as 1.8% for PDGF, a 45-fold difference. Furthermore, gels containing either VEGF of Ang-1 produced twice the vascularization response in vivo as gels not containing a growth factor. Thus, those GFs maintained strong physiologic effectiveness.     

Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis

Thalidomide is an antiangiogenic drug and is clinically useful in a number of cancers. However, the molecular mechanism by which thalidomide exerts its antitumor effects is poorly understood. This study was designed to clarify the relationship between antiangiogenesis and antitumor effects of thalidomide and to explore the molecular mechanism for its antitumor activity. We evaluated the effects of thalidomide on the growth of human tumor cells expressing (MCF-7 and HL-60) or not expressing (HeLa and K562) COX-2 in vitro. We also studied the effects of thalidomide on COX-1, COX-2 or bcl-2 expression, TNFalpha, VEGF, GSH and cytochrome c in these cells. Thalidomide could inhibit tumor growth in a concentration-dependent manner in MCF-7 and HL-60; its IC50s for them were 18.36+/-2.34 and 22.14+/-2.15 microM, respectively, while this effect was not observed in HeLa and K562. Thalidomide reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60. Moreover, cells not expressing COX-2 were insensitive to the growth-inhibitory and effects on cytokines of thalidomide. In our mouse xenograft model of OVCAR-3 and HCT-8, we found that thalidomide could decrease intratumoral microvessel density in both tumors; it exerted antitumor effects only on OVCAR-3 expressing COX-2 but did not on HCT-8 not expressing COX-2. Effect of thalidomide on COX-1 and COX-2 in vivo was consistent with that of in vitro. These results demonstrated that thalidomide might inhibit growth of tumors through COX-2 degradation independent of antiangiogenesis.     

miR-132通过靶向KLF7抑制鼻咽癌细胞增殖和迁移

目的 探讨miR-132靶向负调节Kruppel样因子7（KLF7）表达对鼻咽癌（NPC）细胞增殖和迁移的影响。 方法 将NPC细胞CNE-2Z分组：空白组、NC组、miR-132 mimics组、KLF7-OE组和miR-132 mimics+KLF7-OE组。 荧光定量PCR（qPCR）检测NPC组织和细胞及正常鼻咽组织和细胞中miR-132表达,Western blot检测KLF7蛋白表 达。TargetScan 网站预测及双荧光素酶检测验证KLF7与miR-132的靶向关系。CCK-8实验和Transwell 实验检测 CNE-2Z细胞增殖、迁移和侵袭能力,裸鼠成瘤实验、免疫组化法检测CNE-2Z细胞体内生长、瘤内血管情况。结果 鼻咽癌组织较正常鼻咽组织miR-132表达水平降低,KLF7蛋白表达增加;鼻咽癌CNE-2Z细胞较正常鼻咽上皮细胞 NP69 miR-132表达水平降低,KLF7蛋白表达增加（P＜0.05）。TargetScan预测及双荧光素酶检测显示,KLF7是miR- 132的靶基因。相比空白组、NC组,miR-132 mimics组CNE-2Z细胞中KLF7蛋白表达水平,36、48、60 h细胞增殖活 力,迁移和侵袭数量,肿瘤体积及微血管密度（MVD）显著降低（P＜0.05）,KLF7-OE组结果均相反（P＜0.05）。相比 miR-132 mimics组,miR-132 mimics+KLF7-OE组KLF7蛋白表达水平,36、48、60 h细胞增殖活力,迁移和侵袭数量、 肿瘤体积及MVD显著升高（P＜0.05）。结论 miR-132可通过负调控KLF7表达,影响NPC细胞的增殖、迁移及侵袭。     

Antitumor efficacy of FK228, a novel histone deacetylase inhibitor,depends on the effect on expression of angiogenesis factors

It has been recently demonstrated that histone deacetylase inhibitors inhibit angiogenesis, but their mechanism of action has not been characterized well. In this study, we examined the in vitro and in vivo effects of FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo-[8,7,6]-tricos-16-ene-3,6,9,19,22-pentanone; FR901228, depsipeptide], an HDAC inhibitor, on the expression of angiogenesis factors in FK228-sensitive PC-3 prostate and FK228-resistant ACHN renal cancer cells. FK228 suppressed the expression of VEGF mRNA in PC-3 cells, but not in ACHN cells. FK228 also suppressed the expression of basic fibroblast growth factor (bFGF) mRNA in both PC-3 and ACHN cells. Under conditions of hypoxia, FK228 suppressed the expression of VEGF mRNA without modulating the expression of hypoxia-inducible factor-1 alpha mRNA in PC-3 cells. FK228 induced the highest acetylation of histone H3 and H4 in the P2 region of the VEGF promoter, which includes the hypoxia-inducible factor-1 alpha binding site that plays an important role in regulating the expression of VEGF gene. Moreover, FK228 reduced the amount of VEGF and bFGF protein, and their mRNA levels in PC-3 xenograft implanted in nude mice, but did not reduce them in ACHN xenograft. In conclusion: (i) FK228 showed a suppressive effect on the expression of angiogenesis factors, such as VEGF and bFGF, in PC-3 xenograft but not in ACHN xenograft, which suggests that the effect on the expression of angiogenesis factors is important for the antitumor efficacy of FK228; (ii) FK228 caused histone acetylation of the VEGF promoter regions, which may contribute to the suppression of VEGF gene expression.     

低分子肝素纳米粒子抑制兔血管平滑肌细胞增殖

目的 探讨低分子肝素(LMWH)纳米粒子抑制血管平滑肌细胞(VSMC)增殖的作用及可能的作用机制.方法 建立32只兔颈内静脉-颈动脉移植模型,并随机分为生理盐水灌注组(A)、LMWH灌注组(B)、生理盐水灌注+术后皮下注射LMWH组(C)、LMWH纳米粒子灌注组(D),每组8只.术后4周末截取移植静脉,行免疫组化检测增殖细胞核抗原(PCNA)蛋白的表达;并行RT-PCR检测移植血管单核细胞趋化蛋白-1(MCP-1)、碱性成纤维细胞生长因子(bFGF)、血小板源性牛长因子(PDGF)基因mRNA的表达.结果 与A、B、C三组相比,D组的PCNA阳性细胞指数明显降低(P<0.05),其MCP-1、bFGF、PDGF基因mRNA的表达水平也低于另外三组(P<0.05).结论 LMWH纳米粒子通过抑制平滑肌细胞的增殖与迁移而抑制了血管移植后内膜增生.其作用机制可能是通过降低MCP-1、bFGF、PDGF基因mRNA的表达而实现的.